Global pharma manufacturer · Africa and Asia
Procurement timing and regulatory strategy are the same decision.
Vaccine access across six global markets
6 marketsUNICEF and GAVI procurement cycles
AI-native market entry platform for pharma, biotech and medtech teams. Vantro reads 90+ markets and all 50 US states and DC, and hands you a cited decision.
Every dimension cited to primary sources
How we source ›See what a brief gives you
Enter, but sequence around the registration clock.
Class II under RDC 751/2022. Filed by a Brazilian holder, not by you.
↗ ANVISA, RDC 751/2022The clock starts at a complete dossier. Incomplete filings restart it.
↗ ANVISA, review periodsListing follows registration rather than gating it.
↗ Ministry of Health, SUSA ceiling by category, set against an international basket.
↗ CMED, Resolution 1/2017Usually the distributor, which means the distributor owns the licence.
↗ ANVISA, holder rulesPublished duty, and a different answer inside the Manaus free zone.
↗ Receita Federal| Dimension | |||
|---|---|---|---|
| Regulatory | Moderate | Ready | Ready |
| Timeline | Complex | Ready | Moderate |
| Procurement | Ready | Moderate | Ready |
| Pricing | Complex | Moderate | Moderate |
| Local partner | Ready | Ready | Moderate |
| Recommended order | 2nd | 1st | 3rd |
Abridged evaluation. Both of your clearances qualify.
↗ HSACE evidence accepted. Licence sits with a local representative.
↗ MDANo local representative required, which is rare.
↗ Health CanadaThe establishment licence takes longer than the listing it enables.
↗ SAHPRAOne central licence, then a state licence for each state.
↗ CDSCOLever 1 · price band
Lever 2 · evidence strength
Directional model estimate, not a computed or sourced result. Figures above are real output measured on production for this product and market.
Four payers, four different questions.
Assessed against the comparator the G-BA names, not the one you chose.
↗ G-BA, AMNOGThe model matters as much as the trial, and it is built rather than reported.
↗ NICE methods guideJudged against what is already listed. A placebo comparator usually fails.
↗ CONITECReview and price negotiation are separate steps, and both take time.
↗ CDA-AMCExample output. Every live brief runs on your own product and markets, and every dimension is cited or marked as an estimate.
Run a brief ›Turn the answer into a launch
One page, the verdict and the six dimensions, every claim cited or marked.
| CO | BR | |
|---|---|---|
| Regulatory | Ready | Mod |
| Timeline | Ready | Cx |
| Pricing | Mod | Cx |
The Regulatory Tracker watches the regulators in your markets and tells you what moved.
Built on primary sources
Six dimensions, rated the same way in every market and cited to the regulator, buyer or tax authority that publishes them.
The practice behind the platform
With manufacturers, and with WHO, World Bank and UNICEF programmes across global markets.
Global pharma manufacturer · Africa and Asia
Procurement timing and regulatory strategy are the same decision.
Vaccine access across six global markets
Medtech diagnostics entry sequenced across Kenya, Nigeria and South Africa.
An intergovernmental AI strategy, benchmarked against six peer emergency centres.
Health financing strategy for a South Asian market, built on system performance data.
Vetted regulatory, market access and distribution experts, matched to your product and markets.
Find an expert ›Pricing
2 generations with a free account
Billed monthly, cancel any time
Scoped to your team
A single market report from a consultancy, $20,000 to $40,000 per market → Vantro, every market, from $399 a month
Pick a product and a market. Your first two generations are free, with no credit card and no sales call.